Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $314
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on United Therapeutics (NASDAQ:UTHR) but lowered the price target from $318 to $314.
November 02, 2023 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
United Therapeutics' price target has been lowered by Morgan Stanley from $318 to $314, though the Overweight rating is maintained.
The news is directly about United Therapeutics. The lowering of the price target might have a negative impact on the stock price in the short term. However, the maintained Overweight rating indicates that the analyst still sees the stock as a good investment, which could offset the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100